search
Back to results

Short Stature Related Distress

Primary Purpose

Idiopathic Short Stature, Self Image

Status
Completed
Phase
Phase 4
Locations
Israel
Study Type
Interventional
Intervention
GH treatment (Genotropin)
1 year treatment with placebo followed by optional 3 years of GH treatment
Sponsored by
Rabin Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Idiopathic Short Stature focused on measuring Idiopathic Short stature, Self Image, GH therapy, Psychological distress

Eligibility Criteria

8 Years - 17 Years (Child)MaleDoes not accept healthy volunteers

Inclusion Criteria:

1 Segment 1 :Boys at the age range of 8-13 years 2. Segment 2: Boys at the age range of 12-17 years 3. Tanner stage 1 (segment 1 only) 4. more than 2 SD's (standard deviation) below the average height

Exclusion Criteria:

  1. Mental retardation,
  2. Psychiatric illness,
  3. Lack of informed consent\assent.
  4. Health status that required chronic treatment with steroids

Sites / Locations

  • Schneider Children's Medical center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

No Intervention

Arm Label

GH treatment

Placebo

Non treatment group

Arm Description

4 years of GH treatment

1 year treatment with placebo followed by optional 3 years of GH treatment

Outcomes

Primary Outcome Measures

Psychological Distress score
short stature related distress score as measured by the Height Perception Pictures Test
Psychological Distress score
short stature related distress score as measured by the Rosenberg Self-Esteem Scale
Psychological Distress score
short stature related distress score as measured by the Quality of Life questionnaire
Psychological Distress score
short stature related distress score as measured by Silhouette Apperception Technique questionnaire

Secondary Outcome Measures

Perceived self image score
Perceived self image score as measured through Single Category Implicit Association Test
Perceived self image score
Perceived self image score as measured through the Masculine Self Image questionnaire

Full Information

First Posted
November 16, 2010
Last Updated
December 18, 2017
Sponsor
Rabin Medical Center
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT01246219
Brief Title
Short Stature Related Distress
Official Title
The Influence of Growth Hormone (GH) Therapy on Short Stature Related Distress a Prospective Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
October 2011 (Actual)
Primary Completion Date
November 2017 (Actual)
Study Completion Date
November 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rabin Medical Center
Collaborators
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The research aims to provide data on gender-related psychological impact of GH (Growth Hormone)treatment. Implicit measurable psychological metrics of the therapy outcome on males are to be evaluated in a Prospective Randomized Controlled Trial. As a secondary axis of the study, the investigators aim to provide descriptive documentation of the unique distress signal manifestation implicitly shown by Idiopathic Short Stature (ISS) boys and suggest methods of early detection and measurement of such manifestations that can be used to cement guidelines for the treatment in GH.
Detailed Description
Study Design: A prospective randomized, double blind, placebo controlled trial design, comparing four research groups, with 4 repeated psychological measures (before treatment, after 3 months,after 1 year, and at the end of treatment, after 4 years). The study will be divided into two segments: Segment 1:double blind, placebo controlled, will include the first 60 ISS (Idiopathic Short Stature)recruited patients. Patients in this segment will be randomized to one of the growth hormone treatment groups in a ratio of 2:1. 40 patients will be treated 4 years with GH and 20 patients will be treated with placebo at the first year of the study and will have the option to start GH treatment after one year, for a duration of 3 years. Segment 2:after the enrollment to segment 1 will end, enrollment to segment 2 will begin.Participants in segment 2 (patients with ISS and short stature) will serve as control groups and therefore will not be treated with growth hormone. Patients in Segment 2 will be evaluated only once. The 4 repeated psychological evaluations (before treatment,after 3 months, after 1 year, and at the end of treatment, after 4 years)will include the following: Implicit Association Test Masculine Self Image Pictures Projective Test The Rosenberg Self Esteem Scale-a self report measure of explicit self- esteem Quality of Life Questionnaire Silhouette Apperception Technique (SAT)- a self report measure assessing children's and adolescent's perception of their own body size compared with that of their age-related peers Child Behavior Checklist

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Idiopathic Short Stature, Self Image
Keywords
Idiopathic Short stature, Self Image, GH therapy, Psychological distress

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GH treatment
Arm Type
Experimental
Arm Description
4 years of GH treatment
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
1 year treatment with placebo followed by optional 3 years of GH treatment
Arm Title
Non treatment group
Arm Type
No Intervention
Intervention Type
Drug
Intervention Name(s)
GH treatment (Genotropin)
Intervention Description
4 years treatment with GH
Intervention Type
Drug
Intervention Name(s)
1 year treatment with placebo followed by optional 3 years of GH treatment
Intervention Description
1 year treatment with placebo followed by optional 3 years of GH treatment
Primary Outcome Measure Information:
Title
Psychological Distress score
Description
short stature related distress score as measured by the Height Perception Pictures Test
Time Frame
After 4 years of treatment
Title
Psychological Distress score
Description
short stature related distress score as measured by the Rosenberg Self-Esteem Scale
Time Frame
After 4 years of treatment
Title
Psychological Distress score
Description
short stature related distress score as measured by the Quality of Life questionnaire
Time Frame
After 4 years of treatment
Title
Psychological Distress score
Description
short stature related distress score as measured by Silhouette Apperception Technique questionnaire
Time Frame
After 4 years of treatment
Secondary Outcome Measure Information:
Title
Perceived self image score
Description
Perceived self image score as measured through Single Category Implicit Association Test
Time Frame
After 4 years of treatment
Title
Perceived self image score
Description
Perceived self image score as measured through the Masculine Self Image questionnaire
Time Frame
After 4 years of treatment

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1 Segment 1 :Boys at the age range of 8-13 years 2. Segment 2: Boys at the age range of 12-17 years 3. Tanner stage 1 (segment 1 only) 4. more than 2 SD's (standard deviation) below the average height Exclusion Criteria: Mental retardation, Psychiatric illness, Lack of informed consent\assent. Health status that required chronic treatment with steroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Moshe Phillip, Prof
Organizational Affiliation
Rabin Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Schneider Children's Medical center
City
Petach-Tikva
ZIP/Postal Code
49202
Country
Israel

12. IPD Sharing Statement

Citations:
PubMed Identifier
30721549
Citation
Shemesh-Iron M, Lazar L, Lebenthal Y, Nagelberg N, Tenenbaum A, Ezra R, Leffler N, Yackobovitch-Gavan M, Schoenberg-Taz M, Phillip M. Growth hormone therapy and short stature-related distress: A randomized placebo-controlled trial. Clin Endocrinol (Oxf). 2019 May;90(5):690-701. doi: 10.1111/cen.13944. Epub 2019 Mar 7.
Results Reference
derived

Learn more about this trial

Short Stature Related Distress

We'll reach out to this number within 24 hrs